The health and economic burden of haemophilia in Belgium: a rare, expensive and challenging disease

Last updated on 23-8-2019 by Anonymous (not verified)

Public Access


Peer reviewed scientific article



BACKGROUND: Haemophilia is a rare hereditary haemorrhagic disease that requires regular intravenous injections of clotting factor (CF) concentrates. This study sought to estimate the health and economic burden of haemophilia in Belgium. This is the first study of its type to be conducted, and reflects the Belgian authorities’ growing interest for haemophilia as part of their priority planning for rare and chronic diseases. METHODS: A probabilistic model was developed in order to estimate the lifetime haemophilia burden for the 2011 birth-year Belgian cohort. The health burden was initial…

Associated health topics:

QR code

QR code for this page URL